Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24368139 | 1.00 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL10567786 | 0.98 | HSD17B10 (0.87) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL20564592 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL3873222 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL9193218 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL15935 | 0.98 | HSD17B10 (0.95) | HSD17B10KDM4EALOX15TSHRGLA | |
| Hydrochloric Acid SCHEMBL1128463 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL15572215 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL6858111 | 0.95 | HSD17B10 (1.00) | HSD17B10KDM4EALOX15TSHRGLA | |
| SCHEMBL5762765 | 0.95 | HSD17B10 (0.91) | HSD17B10KDM4EALOX15TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036881-A | Somatostatin receptor-targeting compounds and uses thereof | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026098617-A1 | RADIOPHARMACEUTICAL TARGETING CARBONIC ANHYDRASE IX PROTEIN | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4696686-A1 | FAPI THERANOSTIC COMPOUNDS ASSEMBLED WITH TETRAZINE LIGATION | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | claimed |
| EP-4696680-A1 | DUAL-FUNCTIONAL TETRAZINE COMPOUNDS FOR VERSATILE RADIOLABELING WITH RADIOMETALS AND RADIOHALOGENS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | claimed |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | claimed |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | claimed |
| EP-4667019-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL, AND SYNTHESIS AND USE THEREOF | Norroy Bioscience Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| WO-2025242715-A1 | METHOD FOR RAPIDLY PROVIDING PYRIDAZINES FROM TETRAZINES AND CIS-DIENOPHILES | TETRAKIT TECHNOLOGIES APS (DK) | 2025-11-27 | — | — | WO | claimed |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-11-27 | — | — | US | claimed |
| US-20050036947-A1 | polyamino acid, wherein at least 90 percent of the amino acid residues are conjugated to signal-generating moieties attached to signal-controlling moieties via bonds that are cleavable by a physiological substance produced by the target; used in detecting and/or diagnosing of diseases; MRI | GENERAL ELECTRIC COMPANY | 2005-02-17 | — | — | US | claimed |
| WO-2005004992-A2 | MAGNETIC RESONANCE CONTRAST-ENHANCING AGENTS AND METHOD FOR DETECTING AND IMAGING ARTHEROSCLEROTIC PLAQUE | GENERAL ELECTRIC COMPANY (A NEW YORK CORPORATION) (US) | 2005-01-20 | — | — | WO | claimed |
| US-20040265235-A1 | Magnetic resonance contrast-enhancing agents and method for detecting and imaging artherosclerotic plaque | GENERAL ELECTRIC COMPANY | 2004-12-30 | — | — | US | claimed |
| US-20040022735-A1 | Enzyme activated contrast agents | GENERAL ELECTRIC COMPANY | 2004-02-05 | — | — | US | claimed |
| JP-2833766-B2 | — | — | 1998-12-09 | — | — | JP | claimed |
| EP-0664819-B1 | CHELATING POLYMERS | NYCOMED IMAGING AS (NO) | 1997-08-06 | — | — | EP | claimed |
| US-4885363-A | RADIOPHARMACEUTICAL IMAGING; MEDICAL DIAGNOSIS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | claimed |
| WO-1989000557-A1 | AMINOPOLYCARBOXYLIC ACIDS AND DERIVATIVES THEREOF | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1989-01-26 | — | — | WO | claimed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | claimed |
| EP-0232751-A1 | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs | E.R. Squibb & Sons, Inc. (US) | 1987-08-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | HSD17B10 205/4885KDM4E 4193/4885ALOX15 4788/4885 |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | KLK3, FOLH1, MPI | HSD17B10 2476/4885KDM4E 3642/4885ALOX15 4151/4885 |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, ACP3 | HSD17B10 3549/4885KDM4E 2409/4885ALOX15 3705/4885 |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | PSMA1, ACP3, FOLH1 | HSD17B10 3303/4885KDM4E 3947/4885ALOX15 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.